ABSTRACT
ObjectiveTo investigate the expression of the long non-coding RNA (lncRNA) EXOC7 in serum and liver biopsy tissue of patients with nonalcoholic fatty liver (NAFLD) and its clinical significance. MethodsA total of 120 patients who underwent liver biopsy in The Affiliated Hospital of Southwest Medical University from January 1, 2013 to December 31, 2018 and were diagnosed with NAFLD based on imaging and histopathology were enrolled, among whom 47 had nonalcoholic fatty liver (NAFL) and 73 had nonalcoholic steatohepatitis (NASH). A total of 50 liver disease patients without steatosis or steatohepatitis were enrolled as control group. Real-time PCR was used to measure the expression of lncRNA EXOC7 in liver tissue and serum. The t-test was used for comparison of continuous data between two groups; an analysis of variance was used for comparison between multiple groups, and the SNK-q test was used for further comparison between two groups. A chi-square test was used for comparison of categorical data between groups. A Pearson correlation analysis was used to investigate the correlation between lncRNA EXOC7 and biochemical parameters. The receiver operating characteristic (ROC) curve was plotted to investigate the diagnostic value of lncRNA EXOC7. ResultsCompared with the control group, the patients with NAFL or NASH had significant increases in the expression of lncRNA EXOC7 in liver tissue and serum (all P＜0.05), and the level of such expression increased with the aggravation of hepatic steatosis and inflammation (F=19.96, P＜0.05). The correlation analysis showed that the expression of lncRNA EXOC7 was positively correlated with total triglyceride and low-density lipoprotein cholesterol (r=0.785 and r=0.847, both P＜0.001) and was negatively correlated with high-density lipoprotein cholesterol and insulin sensitivity index (r=-0.726 and -0.709, both P＜0.001). LncRNA EXOC7 had an area under the ROC curve of 0.812 (95% confidence interval: 0.599-0.915, P＜0001), a sensitivity of 8542%, and a specificity of 81.17% in the diagnosis of NAFLD. ConclusionLncRNA EXOC7 is highly expressed in patients with NAFLD, and the expression of lncRNA EXOC7 increases with the aggravation of hepatic steatosis and inflammation, suggesting that lncRNA EXOC7 may be a potential new target for the prevention and treatment of NAFLD.
ABSTRACT
Objective To study treatment of massive variceal bleeding secondary to localized pancreatitis-associated portal hypertension (MVBPAPH).Methods A retrospective study on the clinical data of patients with MVBPAPH was carried out.Of 24 patients with MVBPAPH,20 had pancreatic pseudocysts.12 were operated after failure of treatment with endovascular intervention for variceal bleeding (including 10 patients with splenectomy and gastric fundus-body peripheral vessels amputation and 2 patients with pancreatic pseudocystogastrostomy).8 patients underwent partial splenic embolization and left gastroepiploic artery embolization.4 patients directly underwent splenectomy and gastric fundus-body peripheral vessels amputation for variceal bleeding.Results Left pleural effusion developed in 5 patients who underwent arterial embolization.Left pleural effusion and lung infection occurred in 2 patients who underwent operation.All patients recovered well and were discharged home.During the follow-up period of 2 to 72 months,no rebleeding occurred in these patients (including 2 patients had passed little interval melena).Gastroscopy re-examination showed that variceal veins were not found in 18 patients.Variceal veins which were detected in the remaining 6 patients were obviously less severe.Conclusion Individualized treatment should be given to patients with MVBPAPH and according to the specific type of pancreatitis and the onset time of any accompanying pseudocyst.
ABSTRACT
ObjectiveTo investigate the expression of the long non-coding RNA (lncRNA) EXOC7 in serum and liver biopsy tissue of patients with nonalcoholic fatty liver (NAFLD) and its clinical significance. MethodsA total of 120 patients who underwent liver biopsy in The Affiliated Hospital of Southwest Medical University from January 1, 2013 to December 31, 2018 and were diagnosed with NAFLD based on imaging and histopathology were enrolled, among whom 47 had nonalcoholic fatty liver (NAFL) and 73 had nonalcoholic steatohepatitis (NASH). A total of 50 liver disease patients without steatosis or steatohepatitis were enrolled as control group. Real-time PCR was used to measure the expression of lncRNA EXOC7 in liver tissue and serum. The t-test was used for comparison of continuous data between two groups; an analysis of variance was used for comparison between multiple groups, and the SNK-q test was used for further comparison between two groups. A chi-square test was used for comparison of categorical data between groups. A Pearson correlation analysis was used to investigate the correlation between lncRNA EXOC7 and biochemical parameters. The receiver operating characteristic (ROC) curve was plotted to investigate the diagnostic value of lncRNA EXOC7. ResultsCompared with the control group, the patients with NAFL or NASH had significant increases in the expression of lncRNA EXOC7 in liver tissue and serum (all P＜0.05), and the level of such expression increased with the aggravation of hepatic steatosis and inflammation (F=19.96, P＜0.05). The correlation analysis showed that the expression of lncRNA EXOC7 was positively correlated with total triglyceride and low-density lipoprotein cholesterol (r=0.785 and r=0.847, both P＜0.001) and was negatively correlated with high-density lipoprotein cholesterol and insulin sensitivity index (r=-0.726 and -0.709, both P＜0.001). LncRNA EXOC7 had an area under the ROC curve of 0.812 (95% confidence interval: 0.599-0.915, P＜0001), a sensitivity of 8542%, and a specificity of 81.17% in the diagnosis of NAFLD. ConclusionLncRNA EXOC7 is highly expressed in patients with NAFLD, and the expression of lncRNA EXOC7 increases with the aggravation of hepatic steatosis and inflammation, suggesting that lncRNA EXOC7 may be a potential new target for the prevention and treatment of NAFLD.